TX-FLUENCE
14.9.2022 14:31:41 CEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its collaboration with Westlandse Plantenkwekerij (WPK), a large Dutch propagator specializing in young plant cultivation for greenhouse horticulture in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005286/en/
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors. (Photo: Business Wire)
Originally founded in the 1930s by Arie van der Arend, WPK is a multi-generational family business now run by van der Arend’s descendants, Erik and Eviek. As a propagator, WPK oversees the seed-to-plant process for vegetable and tray plants for growers throughout Europe. The company’s scientific approach to cultivation has led to decades of success, ultimately driving WPK to enlist Fluence’s help to install research-backed LED lighting at their ’s-Gravenzande facility, jointly owned with Plantenkwekerij P. van Geest, for the very first time.
WPK introduced Fluence’s VYPR Series top lights alongside existing legacy high-pressure sodium (HPS) fixtures to harness the unique control a hybrid lighting approach offers for optimizing environmental factors—including controlling ambient heat. The hybrid lighting model at WPK’s facilities has led to better management of seasonal growing conditions and notable energy savings.
“After installing Fluence’s LED lighting solutions, we learned that young plants thrive in LED-lit environments,” said Erik van der Arend, managing director of WPK. “This has allowed us the flexibility to grow a wide range of crops in the same environment and under the same lighting conditions, decreasing hassle and improving our energy costs. The transition to Fluence has helped improve plant quality and speed of development, ensuring our customers get a uniform product that is consistently excellent.”
In collaboration with Fluence’s horticultural lighting experts, WPK fine-tuned the LEDs’ spectra to optimize operational costs while maintaining superior quality for the grower’s tomato, cucumber, pepper and flower crops. Early results show that WPK is realizing an estimated electricity savings between 40 and 50% by using two-thirds Fluence LED fixtures and one-third HPS in the greenhouse. Additionally, WPK increased total light levels by 30% due to the overall efficiency of LED technology. The post-installation harvests produced more compact, generative and vigorous plants that were darker or richer in color.
“The interesting thing about Fluence’s lighting technology is the right degree of cooling—the luminaire doesn’t get very hot,” van der Arend added. “Moreover, the spectrum is widely applicable.”
“When you work with Fluence, you’re not just buying a standalone LED light. You’re tapping into a network of leading lighting and horticultural experts who can help you create the right conditions to optimize your cultivation environment,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “That’s why we love working with propagators like WPK who share our passion for developing innovative lighting and environmental control strategies.”
For more information about the collaboration, visit here.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About WPK
Westlandse Plantenkwekerij (WPK) is a specialist in vegetable cultivation for professional greenhouse horticulture in Europe. WPK was established in the 1930s and currently has four cultivation facilities: two in 's-Gravenzande (South-Holland) and two in Made (North-Brabant). WPK makes the world a little greener with the cultivation of vegetable plants (such as tomato, pepper and cucumber), tray plants and potted flowering plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
